The pipeline, which covers leukaemia, lymphoma and myeloma, is the largest within the oncology therapy area of pharmaceuticals, says GBI Research
A Wright's stained bone marrow aspirate smear from a person with precursor B-cell acute lymphoblastic leukemia. Credit: VashiDonsk, via Wikimedia Commons
With 1,474 programmes in active development and a total of 477 first-in-class pipeline programmes, haematological cancers pipeline is one of the strongest in oncology, according to business intelligence provider GBI Research.
The company’s latest report states that cytokine signalling targets make up the greatest proportion of pipeline and first-in-class programs, followed in both instances by kinases.
These two target categories are intrinsically linked with components of immune response, and are responsible for the majority of targets, in part due to the nature of haematological cancers and their action on immune cells.
Additionally, much of the promising potential within the haematological cancers area revolves around targeted immunotherapies.
It is not uncommon for products being developed for this therapy area to be tested across multiple indications.
Callum Dew, Associate Analyst for GBI Research, explains: “As these disorders affect the immune cells within the blood and bone marrow, there is a high degree of pathophysiological crossover between the separate types of malignancy within haematological cancers, so it is not uncommon for products being developed for this therapy area to be tested across multiple indications.”
214 first-in-class programs are being developed for a single indication but 229 are in development for two or more haematological cancer indications, highlighting the versatility of current pipeline programmes.
With regard to individual molecular targets in the pipeline, 27.3% are first-in-class, which is a greater proportion than the industry average.